Pancreatic Cancer Diagnostic Market Report 2026

The pancreatic cancer diagnostic market size has grown strongly in recent years. It will grow from $4.54 billion in 2025 to $4.93 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to limited availability of advanced diagnostic tools, reliance on conventional imaging and biopsy, low early detection rates, fragmented diagnostic services, hospital-centric diagnostic approach.

The pancreatic cancer diagnostic market size is expected to see strong growth in the next few years. It will grow to $6.95 billion in 2030 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to increasing use of genomic and biomarker-based tests, adoption of ai and machine learning in diagnostics, growth in minimally invasive liquid biopsy techniques, expansion of diagnostic services in hospitals and cancer centers, rise in integrated laboratory and consulting services. Major trends in the forecast period include adoption of advanced genomic testing for pancreatic cancer, integration of ai-powered diagnostic imaging solutions, rise in liquid biopsy and minimally invasive tests, growth in precision medicine diagnostics, expansion of hospital and diagnostic center services.

The rising healthcare spending is expected to drive growth in the pancreatic cancer diagnostic market going forward. Healthcare spending refers to the total financial resources allocated to the healthcare sector within a country, region, or organization. Investment in pancreatic cancer diagnostics helps facilitate early detection, accurate staging, and timely intervention, aiming to improve patient survival rates and outcomes. For instance, in November 2023, the Canadian Institute for Health Information, a Canada-based health information organization, reported that total health spending in Canada was projected to reach $344 billion, or $8,740 per person. This reflects a 2.8% increase compared to 2022, which only saw a 1.5% rise, highlighting a notable rebound in healthcare investment. Therefore, increased healthcare spending is driving the growth of the pancreatic cancer diagnostic market.

Companies in the pancreatic cancer diagnostic market are focusing on innovative solutions such as biomarker-based diagnostic kits to meet the rising demand for early detection, improved accuracy, and better patient outcomes. Biomarker-driven diagnostics identify tumor-specific proteins or genetic markers in blood or tissue samples, offering higher sensitivity and specificity than conventional imaging methods, which often detect pancreatic cancer at advanced stages. For instance, in March 2023, Prestige Biopharma Limited, a Singapore-based biopharmaceutical company, launched the first-in-class PAUF-detecting diagnostic kit. PAUF (Pancreatic Adenocarcinoma Upregulated Factor) is a tumor-specific biomarker associated with early metastasis and is overexpressed in about 80% of pancreatic cancer cases. Preliminary studies by Prestige Biopharma’s Innovative Discovery Center (IDC) revealed that PAUF levels in the blood plasma of pancreatic cancer patients are nearly 1.9 times higher than in healthy individuals, demonstrating the kit’s high sensitivity and specificity for early detection.

In January 2024, Bristol-Myers Squibb (BMS), a US-based biopharmaceutical company, acquired Mirati Therapeutics, Inc. for $4.8 billion. This strategic acquisition strengthened BMS’s portfolio by integrating Mirati’s innovative cancer treatment assets, particularly those targeting pancreatic cancer. Through this acquisition, BMS aims to leverage its global scale and resources to accelerate the development and delivery of more effective treatments for cancer patients. Mirati Therapeutics, Inc. is a US-based biotechnology company focused on pancreatic cancer diagnosis and therapy.

Major companies operating in the pancreatic cancer diagnostic market are Hitachi Medical Corporation, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Becton Dickinson and Company, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Laboratory Corporation of America Holdings, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, Biological Dynamics Inc., Berg LLC, Abcodia Ltd., Acobiom, Amplified Sciences LLC, Avant Diagnostics Inc., Axim Biotechnologies Inc., Alaunus Biosciences Inc., Advanced Marker Discovery SL, Anixa Diagnostics Corporation.

North America was the largest region in the pancreatic cancer diagnostic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pancreatic cancer diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pancreatic cancer diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the pancreatic cancer diagnostic market by increasing the cost of imported imaging systems, biopsy devices, and assay kits. Segments such as hospitals, diagnostic centers, and cancer research centers in north america, europe, and asia-pacific are most affected due to reliance on imported high-tech diagnostic equipment. While tariffs elevate equipment costs, they also incentivize local manufacturing, improve supply chain resilience, and promote innovation in cost-effective diagnostic solutions.

The pancreatic cancer diagnostic market research report is one of a series of new reports that provides pancreatic cancer diagnostic market statistics, including pancreatic cancer diagnostic industry global market size, regional shares, competitors with a pancreatic cancer diagnostic market share, detailed pancreatic cancer diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the pancreatic cancer diagnostic industry. This pancreatic cancer diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pancreatic cancer diagnostics involve the procedures and techniques used to detect, classify, and stage pancreatic cancer, helping determine disease severity and guide treatment decisions. These diagnostics are commonly applied to pancreatic adenocarcinoma, squamous cell carcinoma, insulinoma, and other pancreatic cancer types.

The main categories of pancreatic cancer diagnostic products are instruments, consumables, and services. Instruments are tools or devices used during diagnostic procedures to examine or manipulate biological tissue and obtain accurate results. Treatment approaches associated with pancreatic cancer include surgery, chemotherapy, radiation therapy, and targeted therapy, applied to cancer types such as exocrine, adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, colloid carcinoma, and endocrine tumors. Diagnostic methods include imaging tests, biopsies, blood tests, genomic testing, and other assays. These products and services are utilized by hospitals, diagnostic centers, cancer research institutes, academic institutions, ambulatory surgical centers, and other end-users.

The pancreatic cancer diagnostic market includes revenues earned by entities through computerized tomography (CT) scans, Magnetic resonance imaging (MRI), positron emission tomography (PET) scan, and ultrasound. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The pancreatic cancer diagnostic market consists of sales of tumor markers and drugs such as Abraxane, Afinitor, and Capecitabine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.